Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema

Subcutaneous C1‐inhibitor (HAEGARDA, CSL Behring), is a US Food and Drug Administration (FDA)‐approved, highly concentrated formulation of a plasma‐derived C1‐esterase inhibitor (C1‐INH), which, in the phase III Clinical Studies for Optimal Management in Preventing Angioedema with Low‐Volume Subcuta...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Tortorici, Michael A., Pawaskar, Dipti, Pragst, Ingo, Machnig, Thomas, Hutmacher, Matthew, Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Longhurst, Hilary, Sidhu, Jagdev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869560/
https://www.ncbi.nlm.nih.gov/pubmed/29316335
http://dx.doi.org/10.1002/psp4.12271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869560/
https://www.ncbi.nlm.nih.gov/pubmed/29316335
http://dx.doi.org/10.1002/psp4.12271

Ejemplares similares